---

---

published : Previous years    tags : Atopic dermatitis   

save search

---

ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting
Published: 2022-03-18 (Crawled : 12:00) - biospace.com/
ASLN | News | $0.54 0.0% 26K |

Health Technology

| -32.99% | O: 6.42% H: 0.99% C: -2.02%
america als atopic dermatitis dermatitis derm presentation roof

---

Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Atopic Dermatitis
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -7.54% | O: 1.79% H: 0.0% C: 0.0%
lnk0100 als atopic dermatitis ces dermatitis derm 100

---

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis
Published: 2022-02-17 (Crawled : 13:30) - biospace.com/
EVLO | $0.3165 -87.39% 710K |

Health Technology

| -92.09% | O: 1.25% H: 0.0% C: -10.37%
edp1815 phase 2 atopic dermatitis dermatitis derm trial bioscience

---

FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis
Published: 2022-02-10 (Crawled : 07:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -13.25% | O: -0.92% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| 45.11% | O: -0.33% H: 0.0% C: 0.0%
dupixent fda atopic dermatitis dermatitis derm children fda acceptance

---

J&J Incurs $610M Charge for Dropped Atopic Dermatitis Program
Published: 2022-02-03 (Crawled : 16:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M |

Health Technology

| -13.01% | O: 1.26% H: 0.0% C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -11.17% | O: -0.06% H: 0.0% C: 0.0%
atopic dermatitis program dermatitis drop charging

---

Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 206.82% | O: 0.33% H: 3.25% C: 3.2%
INCY | $52.3 -0.98% -0.99% 2.2M |

Health Technology

| -26.88% | O: -0.2% H: 3.93% C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus

---

ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis
Published: 2022-01-20 (Crawled : 22:00) - biospace.com/
ASLN | News | $0.54 0.0% 26K |

Health Technology

| -47.41% | O: -1.01% H: 4.17% C: -4.06%
aslan004 phase 2 als atopic dermatitis dermatitis phase 2b

---

VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2022-01-19 (Crawled : 14:00) - biospace.com/
VYNE | $2.285 -0.65% -0.66% 19K |

Health Technology

| 228.95% | O: 2.19% H: 2.99% C: -5.58%
fmx114 treatment atopic dermatitis dermatitis phase 1b trial therapeutics phase 1 phase 2b

---

ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004
Published: 2022-01-18 (Crawled : 12:30) - aslanpharma.com
ASLN | News | $0.54 0.0% 26K |

Health Technology

| -50.49% | O: 4.85% H: 0.58% C: -8.33%
aslan004 als atopic dermatitis dermatitis

---

Another Atopic Dermatitis Drug Hits the Market as FDA Okays Pfizer's Cibinqo
Published: 2022-01-17 (Crawled : 15:30) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| Email alert Add to watchlist
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| Email alert Add to watchlist
cibinqo fda atopic dermatitis dermatitis drug

---

U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
Published: 2022-01-14 (Crawled : 21:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M |

Health Technology

| -53.19% | O: -1.01% H: 0.0% C: 0.0%
cibinqo fda atopic dermatitis dermatitis

---

U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Published: 2022-01-14 (Crawled : 19:00) - prnewswire.com
ABBV | $166.41 1.06% 0.0% 5.5M |

Health Technology

| Email alert Add to watchlist
rinvoq fda atopic dermatitis dermatitis children order

---

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2022-01-05 (Crawled : 12:30) - globenewswire.com
CNTB | $1.49 -1.97% -2.01% 32K |

Professional, Scientific, and T...

| -73.99% | O: -17.74% H: 0.0% C: 0.0%
cbp-201 phase 2 biopharma atopic dermatitis dermatitis phase 2b trial positive

---

Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Published: 2021-12-21 (Crawled : 07:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M |

Health Technology

| 175.66% | O: 0.2% H: 0.74% C: 0.33%
atopic dermatitis dermatitis skin phase 3

---

Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K |

Health Technology

| -4.51% | O: 3.01% H: 0.28% C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M |

Health Technology

| -5.13% | O: -0.42% H: 0.0% C: 0.0%
REGN | $896.27 0.26% 0.25% 500K |

Health Technology

| 35.54% | O: -1.54% H: 0.0% C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3

---

Allakos Announces Expansion of Lirentelimab Development into Atopic Dermatitis, Chronic Spontaneous Urticaria and Asthma
Published: 2021-11-30 (Crawled : 15:00) - biospace.com/
ALLK | $1.065 0.47% 0.47% 420K |

Health Technology

| -98.65% | O: -0.92% H: 0.0% C: 0.0%
atopic dermatitis expansion dermatitis urticaria

---

Hoth Therapeutics' Enrollment and Dosing in Second Cohort in Phase 1b Human Trial for Atopic Dermatitis Under Way
Published: 2021-11-30 (Crawled : 13:00) - ir.hoththerapeutics.com
HOTH | $1.22 3.39% 3.28% 22K |

Health Technology

| 43.97% | O: 0.06% H: 4.32% C: -1.8%
atopic dermatitis phase 1 dermatitis phase 1b trial therapeutics enroll phase 2b

---

Connect Biopharma Reports Positive Top-Line Results from the Global Phase 2 Clinical Trial of CBP-201 in Patients with Moderate-to-Severe Atopic Dermatitis
Published: 2021-11-18 (Crawled : 23:00) - biospace.com/
CNTB | $1.49 -1.97% -2.01% 32K |

Professional, Scientific, and T...

| -87.44% | O: -2.12% H: 3.04% C: 0.92%
phase 2 biopharma atopic dermatitis positive results dermatitis trial topline

---

VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
Published: 2021-10-19 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.285 -0.65% -0.66% 19K |

Health Technology

| 97.37% | O: -0.88% H: 4.42% C: -1.77%
treatment atopic dermatitis dermatitis trial enroll

---

ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
Published: 2021-10-18 (Crawled : 11:00) - aslanpharma.com
ASLN | News | $0.54 0.0% 26K |

Health Technology

| -68.32% | O: -1.86% H: 4.43% C: 0.63%
treatment dermatitis atopic dermatitis

---

Gainers vs Losers

67%

33%

Top 10 Gainers

GBR | $1.42 31.48% 11.27% 990K |

Energy Minerals

KUKE | $2.88 2.49% 7.64% 360K |

MPLN | $0.6502 -11.74% 4.51% 2.2M |

Finance

CXM 4 | $11.34 -0.44% 4.27% 1.7M |

Information

PVL 4 | $1.47 -0.68% 4.08% 77K |

Energy Minerals

RNR 4 | $224.74 0.85% 3.52% 310K |

Finance

PZG | $0.4431 0.48% 2.91% 150K |

Non-Energy Minerals

DBRG | $17.3 0.06% 1.97% 1.2M |

Finance and Insurance

OSK 4 | $117.72 0.05% 1.96% 370K |

Producer Manufacturing

HYLN 4 | $1.29 -2.27% 1.55% 680K |

Producer Manufacturing

---

Your saved searches

---